Achieve Life Sciences Inc (ACHV) - Total Liabilities
Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) has total liabilities worth $22.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ACHV net asset momentum to track the company's year-over-year net asset growth rate.
Achieve Life Sciences Inc - Total Liabilities Trend (1994–2025)
This chart illustrates how Achieve Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. See ACHV cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Achieve Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Achieve Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hansen Technologies Ltd
AU:HSN
|
Australia | AU$221.29 Million |
|
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
|
China | CN¥1.57 Billion |
|
Changhong Meiling Co Ltd
SHE:000521
|
China | CN¥17.44 Billion |
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩36.31 Billion |
|
Alpargatas S.A
SA:ALPA3
|
Brazil | R$2.83 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥23.58 Billion |
|
Jana Small Finance Bank
NSE:JSFB
|
India | Rs429.78 Billion |
|
Helen of Troy Ltd
NASDAQ:HELE
|
USA | $1.24 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Achieve Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACHV market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Achieve Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Achieve Life Sciences Inc (1994–2025)
The table below shows the annual total liabilities of Achieve Life Sciences Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.27 Million | +14.31% |
| 2024-12-31 | $17.73 Million | -14.82% |
| 2023-12-31 | $20.82 Million | -3.92% |
| 2022-12-31 | $21.67 Million | +11.27% |
| 2021-12-31 | $19.47 Million | +546.55% |
| 2020-12-31 | $3.01 Million | -0.53% |
| 2019-12-31 | $3.03 Million | -7.74% |
| 2018-12-31 | $3.28 Million | +63.04% |
| 2017-12-31 | $2.01 Million | -76.33% |
| 2016-12-31 | $8.50 Million | -59.05% |
| 2015-12-31 | $20.77 Million | -6.58% |
| 2014-12-31 | $22.23 Million | +20.32% |
| 2013-12-31 | $18.48 Million | +16.88% |
| 2012-12-31 | $15.81 Million | -57.42% |
| 2011-12-31 | $37.12 Million | -18.93% |
| 2010-12-31 | $45.79 Million | -0.50% |
| 2009-12-31 | $46.02 Million | +1027.14% |
| 2008-12-31 | $4.08 Million | -69.40% |
| 2007-12-31 | $13.34 Million | -47.57% |
| 2006-12-31 | $25.45 Million | +12.37% |
| 2005-12-31 | $22.65 Million | +548.37% |
| 2004-12-31 | $3.49 Million | +61.84% |
| 2003-12-31 | $2.16 Million | -2.34% |
| 2002-12-31 | $2.21 Million | +84.42% |
| 2001-12-31 | $1.20 Million | -79.34% |
| 2000-12-31 | $5.80 Million | -28.39% |
| 1999-12-31 | $8.10 Million | -28.32% |
| 1998-12-31 | $11.30 Million | +8.65% |
| 1997-12-31 | $10.40 Million | +4.00% |
| 1996-12-31 | $10.00 Million | +14.94% |
| 1995-12-31 | $8.70 Million | -28.69% |
| 1994-12-31 | $12.20 Million | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more